NCT02726789View on ClinicalTrials.gov

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions
Hepatitis B, Chronic
Interventions
DRUG

REP 2139-Ca

the nucleic acid polymer REP 2139 formulated as a calcium chelate complex

DRUG

pegylated interferon

immunotherapy

DRUG

entecavir

local generic entecavir

All Listed Sponsors
lead

Replicor Inc.

INDUSTRY

NCT02726789 - Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B | Biotech Hunter | Biotech Hunter